Scott Dunseth Myers is Chief Executive Officer of Viridian Therapeutics, Inc.\DE. Currently has a direct ownership of 259,500 shares of VRDN, which is worth approximately $5.01 Million. The most recent transaction as insider was on Apr 12, 2023, when has been sold 4,000 shares (Common Stock) at a price of $25.37 per share, resulting in proceeds of $101,480. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 260K
0% 3M change
0% 12M change
Total Value Held $5.01 Million

Scott Dunseth Myers Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 12 2023
BUY
Open market or private purchase
$101,480 $25.37 p/Share
4,000 Added 1.52%
259,500 Common Stock
Mar 13 2023
BUY
Open market or private purchase
$160,325 $29.15 p/Share
5,500 Added 2.11%
255,500 Common Stock
Feb 06 2023
BUY
Grant, award, or other acquisition
-
250,000 Added 50.0%
250,000 Common Stock

Also insider at

AMAG
AMAG PHARMACEUTICALS, INC.
SELB
SELECTA BIOSCIENCES INC Healthcare
HARP
Harpoon Therapeutics, Inc. Healthcare
DVAX
DYNAVAX TECHNOLOGIES CORP Healthcare
ZNTL
Zentalis Pharmaceuticals, Inc. Healthcare
SDM

Scott Dunseth Myers

Chief Executive Officer
Emeryville, CA

Track Institutional and Insider Activities on VRDN

Follow Viridian Therapeutics, Inc.\DE and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRDN shares.

Notify only if

Insider Trading

Get notified when an Viridian Therapeutics, Inc.\De insider buys or sells VRDN shares.

Notify only if

News

Receive news related to Viridian Therapeutics, Inc.\DE

Track Activities on VRDN